Regulation of CD4 + and CD8 + T Cell Biology by Short-Chain Fatty Acids and Its Relevance for Autoimmune Pathology.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic, in vitro, and animal studies
PubMed 35955407 · doi:10.3390/ijms23158272
What was done
This narrative review summarizes findings from in vitro experiments, animal disease models, and human studies examining how gut microbiota-derived short-chain fatty acids (acetate, propionate, butyrate, and valerate) regulate CD4+ and CD8+ T cell function and influence autoimmune and inflammatory diseases.
What was found
The abstract reports no numerical data. It notes that short-chain fatty acids act directly on host T lymphocytes by altering metabolic and epigenetic states, promote regulatory T cell differentiation, stimulate anti-inflammatory interleukin-10 (IL-10) production, and show therapeutic potential in experimental models of inflammatory bowel disease, multiple sclerosis, and diabetes.
Why it matters
The review synthesizes the mechanistic links between microbial metabolites and adaptive immunity, highlighting short-chain fatty acids as potential therapeutic targets for autoimmune disorders.
Limits
The abstract provides no quantitative metrics or search methodology. Findings largely rely on in vitro and animal disease models, which may not directly translate to human clinical outcomes.
Cited by
- supports Short-chain fatty acids such as butyrate, propionate, and acetate act as signaling molecules that modulate the immune system by influencing regulatory T cell (Treg) activity and production.